

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Otrivine Congestion Relief Menthol 0.1% w/v Nasal Spray

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Otrivine Nasal Spray contains 1 mg/ml of xylometazoline hydrochloride.

Each metered-dose spray delivers 0.14 mg of xylometazoline hydrochloride.

Excipients with known effect: polyoxyl hydrogenated castor oil (2.750 mg/ml)

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Nasal Spray (solution)

Metered-dose spray: opalescent, white solution with menthol and eucalyptol (cineole) odour.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

For the relief of nasal congestion due to colds, hay fever or other allergic rhinitis, sinusitis.

To aid drainage of secretions in affections of the paranasal sinuses.

As an adjuvant in otitis media, to decongest the nasopharyngeal mucosa.

To facilitate rhinoscopy.

Otrivine Nasal Spray is indicated in adults and in adolescents over 12 years of age.

4.2 Posology and method of administration

Posology

Paediatric population

Otrivine Nasal Spray should not be used in children aged less than 12 years old.

Method of administration

Otrivine Nasal Spray nasal metered-dose spray

Strength	Age	Posology
0.1%	Adults and adolescents over 12 years of age	1 spray into each nostril, 3 times daily as needed. Do not exceed 3 applications daily into each nostril.

The metered-dose spray permits accuracy of dosage and ensures that the solution is well distributed over the surface of the nasal mucosa. It precludes the possibility of unintentional overdose.

Otrivine should not be used for more than seven consecutive days (see section 4.4).

The recommended dosage should not be exceeded, especially in children and the elderly.

Before the first application, prime the pump by actuating 4 times. Once primed the pump will normally remain charged throughout regular daily treatment periods. Should the spray not be ejected during the full actuation stroke, the pump will need to be reprimed with the same number of actuations as initially performed.

Be careful not to spray in the eyes.

1. Blow the nose gently.
2. Remove protective cap.
3. Do not cut the nozzle. The metered dose spray is ready to prime before use.
4. Hold the bottle upright with thumb under base and nozzle between two fingers.
5. Lean forward slightly and insert the nozzle into a nostril.
6. Spray and breathe in gently through the nose at the same time.
7. Repeat in the other nostril
8. Clean and dry the nozzle before replacing back the cap right after use.

To avoid possible spread of infection, the spray should only be used by one person.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Like other vasoconstrictors, Otrivine Nasal Spray should not be used in patients with trans-sphenoidal hypophysectomy or surgery exposing the dura mater.

Patients with acute coronary disease, hyperthyroidism or narrow angle glaucoma.

Rhinitis sicca and atrophic rhinitis

Use in patients who are receiving monoamine oxidase inhibitors, or within 14 days of stopping such treatments.

Otrivine 0.1% is contraindicated in children aged less than 12 years old.

4.4 Special warnings and precautions for use

Otrivine Nasal Spray, like other sympathomimetic agents, should be used with caution in patients showing a strong reaction to adrenergic substances, as manifested by signs of insomnia, dizziness, tremor, cardiac arrhythmias or elevated blood pressure. Patients with long QT syndrome treated with xylometazoline may be at increased risk of serious ventricular arrhythmias. Like other topical vasoconstrictors, Otrivine Nasal Spray should not be used for more than seven consecutive days: prolonged or excessive use may cause rebound congestion, and/or atrophy of the nasal mucosa.

Do not exceed the recommended dose, especially in children and in the elderly.

Caution is recommended in patients with hypertension, cardiovascular disease, diabetes mellitus, phaeochromocytoma, prostatic hypertrophy, and in patients on tri and tetra-cyclic antidepressant treatment (see section 4.5).

Keep out of the sight and reach of children.

For prevention of cross infection, it is recommended that each product package is used by one person only.

Paediatric population

Otrivine Nasal Spray should not be used in children aged less than 12 years old.

Information concerning excipients

This medicine contains polyoxyl hydrogenated castor oil which may cause skin reactions.

4.5 Interaction with other medicinal products and other forms of interaction

Like for all sympathomimetics, a reinforcement of the systemic effects of xylometazoline by concomitant use of monoamine oxidase inhibitors, tricyclic or tetracyclic antidepressants, may cause an increase in blood pressure due to the cardiovascular effects of these substances and cannot be excluded, especially in case of overdose.

4.6 Fertility, pregnancy and lactation

Pregnancy

In view of its potential systemic vasoconstrictor effect, it is advisable to take the precaution of not using Otrivine Nasal Spray during pregnancy.

Breastfeeding

There is no evidence of any adverse effect on the breast-fed infant. However, it is not known if xylometazoline is excreted in breast milk, therefore caution should be exercised and Otrivine Nasal Spray should be used only under medical advice, while breast-feeding.

Fertility

There are no adequate data for the effects of Otrivine Nasal Spray on fertility and no animal studies are available. As the systemic exposure to xylometazoline hydrochloride is very low, effects on fertility are therefore very unlikely.

4.7 Effects on ability to drive and use machines

Otrivine Nasal Spray has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

The adverse effects listed below are classified by system organ class and frequency according to the following convention: very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$) or very rare ($< 1/10,000$).

MeDRA SOC	Adverse reaction	Frequency
Immune System Disorders	Hypersensitivity reaction (angioedema, rash, pruritus)	Very rare
Nervous System Disorders	Headache	Common
Eye Disorders	Transient visual impairment	Very rare
Cardiac Disorders	Heart rate irregular	Very rare
	Heart rate increased	Very rare
Respiratory, thoracic and mediastinal disorders	Nasal Dryness	Common
	Nasal Discomfort	Common
	Epistaxis	Uncommon
Gastrointestinal disorders	Nausea	Common
General disorders and administration site	Application site burning	Common

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, website: www.hpra.ie.

4.9 Overdose

Symptoms and Signs

Excessive administration of topical xylometazoline hydrochloride or accidental ingestion may cause severe dizziness, perspiration, severely lowered body temperature, headache, bradycardia, hypertension, respiratory depression, coma and convulsions. Hypertension may be followed by hypotension. Small children are more sensitive to toxicity than adults.

Treatment

Appropriate supportive measures should be initiated in all individuals suspected of an overdose, and urgent symptomatic treatment under medical supervision is indicated when warranted. This would include observation of the individual for several hours.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: decongestants for topical use, sympathomimetics, plain.

ATC Code: R01A A07

Mechanism of action and pharmacodynamic effects

Xylometazoline is a sympathomimetic agent acting on alpha-adrenergic receptors in the nasal mucosa. Administered in the nose, it constricts the nasal blood vessels, thereby decongesting the mucosa of the nose and neighbouring regions of the pharynx. This decongests nasal passages and enables patients suffering from blocked nose to breathe more easily through the nose. The effect of Otrivine Nasal Spray begins within a few minutes and lasts for up to 10 hours.

In a double-blind, saline solution controlled study in patients with common cold, the decongestant effect of Otrivine was significantly superior ($p < 0.0001$) to saline solution based on rhinomanometry measurement. Relief of blocked nose developed twice as fast in the Otrivine group compared to saline solution as of 5 minutes post treatment ($p = 0.047$).

Otrivine Nasal Spray is well tolerated, even by patients with a sensitive mucosa, and does not impair the mucociliary function.

Otrivine Nasal Spray contains no preservative. The one-way vacuum pump delivering the metered dose spray is specifically designed to prevent microbial contamination of the content. The nozzle has a special design and a cap with special openings that allow the residual liquid to dry, thus preventing microbial contamination of the next sprayed dose.

Otrivine Nasal Spray contains cooling aromatic vapours of menthol and eucalyptol (cineole) in addition to the active ingredient xylometazoline.

5.2 Pharmacokinetic properties

Plasma concentrations of xylometazoline in man after local nasal application of the product are very low and close to the limit of detection.

5.3 Preclinical safety data

Xylometazoline has no mutagenic effect. No teratogenic effects were shown in a study where xylometazoline was given subcutaneously in mice and rats.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium dihydrogen phosphate dihydrate
Disodium phosphate dodecahydrate
Sodium chloride
Disodium edetate
Levomenthol (Menthol)
Cineole (Eucalyptol)
Sorbitol
Polyoxylhydrogenated castor oil (Macrogol glycerol hydroxystearate)
Purified water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

30 months.

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of container

10ml multidose HDPE bottle mounted with a metered-dose spray pump.

6.6 Special precautions for disposal

No special requirements.

Any unused product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Haleon Ireland Limited,
Clocherane, Youghal Road,
Dungarvan,
Co. Waterford, X35 Y983,
Ireland

8 MARKETING AUTHORISATION NUMBER

PA0678/120/005

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 4th July 2014

Date of last renewal: 3rd July 2019

10 DATE OF REVISION OF THE TEXT

July 2025